Open Access

Positive thyroid antibodies and risk of thyroid cancer: A systematic review and meta‑analysis

  • Authors:
    • Yang Xiao
    • Quan Zhou
    • Yong Xu
    • Song‑Lin Yuan
    • Qing‑An Liu
  • View Affiliations

  • Published online on: June 21, 2019     https://doi.org/10.3892/mco.2019.1886
  • Pages: 234-242
  • Copyright: © Xiao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Previous studies assessing the association between thyroid antibodies and the risk of thyroid cancer (TC) have produced inconsistent results. The present study therefore conducted a meta‑analysis of the available data. PubMed, Embase and the Cochrane Library were searched for the retrieval of relevant studies and a meta‑analysis was conducted to systematically evaluate the association between positive thyroid antibodies and the risk of TC. This search identified 16 articles containing 17 studies on thyroglobulin antibodies (TgAb), which involved a total of 34,488 patients. Positive TgAb was associated with an increased risk of TC [odds ratio (OR)=1.93, 95% confidence interval (CI)=1.64‑2.27, I2=67.2%]. Whether to adjust for confounding factors (gender and thyroid nodule number) was the main cause of heterogeneity. A stronger association between positive TgAb and an increased risk of TC was identified in the studies with an unadjusted thyroid nodule number (OR=2.14, 95% CI=1.82‑2.52), as compared to those with an adjusted thyroid nodule number (OR=1.61, 95% CI=1.29‑2.00; P=0.04). In addition, 12 studies on thyroid peroxidase antibodies (TPOAb) involving 30,007 patients were included. Positive TPOAb was associated with an increased risk of TC (OR=1.50, 95%CI=1.16‑1.95, I2=83.0%). No significant heterogeneity was observed in the PTC group. Positive TgAb is an independent risk factor for TC. The association between positive TPOAb and increased risk of TC needs to be further studied.

References

1 

Frates MC, Benson CB, Doubilet PM, Kunreuther E, Contreras M, Cibas ES, Orcutt J, Moore FD Jr, Larsen PR, Marqusee E and Alexander EK: Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab. 91:3411–3417. 2006. View Article : Google Scholar : PubMed/NCBI

2 

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI

3 

Morris LG, Tuttle RM and Davies L: Changing trends in the incidence of thyroid cancer in the united states. JAMA Otolaryngol Head Neck Surg. 142:709–711. 2016. View Article : Google Scholar : PubMed/NCBI

4 

La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F and Negri E: Thyroid cancer mortality and incidence: A global overview. Int J Cancer. 136:2187–2195. 2015. View Article : Google Scholar : PubMed/NCBI

5 

Du L, Wang Y, Sun X, Li H, Geng X, Ge M and Zhu Y: Thyroid cancer: Trends in incidence, mortality and clinical-pathological patterns in Zhejiang Province, Southeast China. BMC Cancer. 18:2912018. View Article : Google Scholar : PubMed/NCBI

6 

Karatzas T, Vasileiadis I, Zapanti E, Charitoudis G, Karakostas E and Boutzios G: Thyroglobulin antibodies as a potential predictive marker of papillary thyroid carcinoma in patients with indeterminate cytology. Am J Surg. 212:946–952. 2016. View Article : Google Scholar : PubMed/NCBI

7 

Azizi G and Malchoff CD: Autoimmune thyroid disease: A risk factor for thyroid cancer. Endocr Pract. 17:201–209. 2011. View Article : Google Scholar : PubMed/NCBI

8 

Vasileiadis I, Boutzios G, Charitoudis G, Koukoulioti E and Karatzas T: Thyroglobulin antibodies could be a potential predictive marker for papillary thyroid carcinoma. Ann Surg Oncol. 21:2725–2732. 2014. View Article : Google Scholar : PubMed/NCBI

9 

Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, Fatemi S, LoPresti JS and Nicoloff JT: Serum thyroglobulin autoantibodies: Prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 83:1121–1127. 1998. View Article : Google Scholar : PubMed/NCBI

10 

Kim ES, Lim DJ, Baek KH, Lee JM, Kim MK, Kwon HS, Song KH, Kang MI, Cha BY, Lee KW and Son HY: Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules. Thyroid. 20:885–891. 2010. View Article : Google Scholar : PubMed/NCBI

11 

Liu Y, Li C, Zhao W and Wang Y: Hashimoto's thyroiditis is an important risk factor of papillary thyroid microcarcinoma in younger adults. Horm Metab Res. 49:732–738. 2017. View Article : Google Scholar : PubMed/NCBI

12 

Ernaga-Lorea A, Hernandez-Morhain MC, Anda-Apinaniz E, Pineda-Arribas JJ, Migueliz-Bermejo I, Eguílaz-Esparza N and Irigaray-Echarri A: Prognostic value of change in anti-thyroglobulin antibodies after thyroidectomy in patients with papillary thyroid carcinoma. Clin Transl Oncol. 20:740–744. 2018. View Article : Google Scholar : PubMed/NCBI

13 

Trimboli P, Zilioli V, Imperiali M and Giovanella L: Thyroglobulin autoantibodies before radioiodine ablation predict differentiated thyroid cancer outcome. Clin Chem Lab Med. 55:1995–2001. 2017. View Article : Google Scholar : PubMed/NCBI

14 

Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M and Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2009, simplehttp://www.ohri.ca/programs/clinical_epidemiology/oxford.htm

15 

Zhu C, Li S, Gao X, Zhu G, Song M and Gao F: Retrospective analysis of thyroid nodules: Thyroid cancer risk factors in suzhou, china. Clin Lab. 64:333–338. 2018. View Article : Google Scholar : PubMed/NCBI

16 

Liu J, Zheng D, Li Q, Tang X, Luo Z, Yuan Z, Gao L and Zhao J: A predictive model of thyroid malignancy using clinical, biochemical and sonographic parameters for patients in a multi-center setting. BMC Endocr Disord. 18:17–23. 2018. View Article : Google Scholar : PubMed/NCBI

17 

Zhao H, Li H and Huang T: High urinary iodine, thyroid autoantibodies, and thyroid-stimulating hormone for papillary thyroid cancer risk. Biol Trace Elem Res. 184:317–324. 2017. View Article : Google Scholar : PubMed/NCBI

18 

Zeng R, Shou T, Yang KX, Shen T, Zhang JP, Zuo RX, Zheng YQ and Yan XM: Papillary thyroid carcinoma risk factors in the yunnan plateau of southwestern China. Ther Clin Risk Manag. 12:1065–1074. 2016. View Article : Google Scholar : PubMed/NCBI

19 

He LZ, Zeng TS, Pu L, Pan SX, Xia WF and Chen LL: Thyroid hormones, autoantibodies, ultrasonography, and clinical parameters for predicting thyroid cancer. Int J Endocrinol. 2016:82158342016. View Article : Google Scholar : PubMed/NCBI

20 

Qin J, Yu Z, Guan H, Shi L, Liu Y, Zhao N, Shan Z, Han C, Li Y and Teng W: High thyroglobulin antibody levels increase the risk of differentiated thyroid carcinoma. Dis Markers. 2015:6486702015. View Article : Google Scholar : PubMed/NCBI

21 

Li T, Sheng J, Li W, Zhang X, Yu H, Chen X, Zhang J, Cai Q, Shi Y and Liu Z: A new computational model for human thyroid cancer enhances the preoperative diagnostic efficacy. Oncotarget. 6:28463–28477. 2015.PubMed/NCBI

22 

Grani G, Calvanese A, Carbotta G, D'Alessandri M, Nesca A, Bianchini M, Del Sordo M, Vitale M and Fumarola A: Thyroid autoimmunity and risk of malignancy in thyroid nodules submitted to fine-needle aspiration cytology. Head Neck. 37:260–264. 2014. View Article : Google Scholar : PubMed/NCBI

23 

Azizi G, Keller JM, Lewis M, Piper K, Puett D, Rivenbark KM and Malchoff CD: Association of hashimoto's thyroiditis with thyroid cancer. Endocr Relat Cancer. 21:845–852. 2014. View Article : Google Scholar : PubMed/NCBI

24 

Wu X, Lun Y, Jiang H, Gang Q, Xin S, Duan Z and Zhang J: Coexistence of thyroglobulin antibodies and thyroid peroxidase antibodies correlates with elevated thyroid-stimulating hormone level and advanced tumor stage of papillary thyroid cancer. Endocrine. 46:554–560. 2013. View Article : Google Scholar : PubMed/NCBI

25 

Lun Y, Wu X, Xia Q, Han Y, Zhang X, Liu Z, Wang F, Duan Z, Xin S and Zhang J: Hashimoto's thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis. Otolaryngol Head Neck Surg. 148:396–402. 2013. View Article : Google Scholar : PubMed/NCBI

26 

Boi F, Minerba L, Lai ML, Marziani B, Figus B, Spanu F, Borghero A and Mariotti S: Both thyroid autoimmunity and increased serum TSH are independent risk factors for malignancy in patients with thyroid nodules. J Endocrinol Invest. 36:313–320. 2013.PubMed/NCBI

27 

Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC and Franklyn JA: Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab. 91:4295–4301. 2006. View Article : Google Scholar : PubMed/NCBI

28 

Lau J, Ioannidis JP, Terrin N, Schmid CH and Olkin I: The case of the misleading funnel plot. BMJ. 333:597–600. 2006. View Article : Google Scholar : PubMed/NCBI

29 

Hosseini S, Payne RJ, Zawawi F, Mlynarek A, Hier MP, Tamilia M and Forest VI: Can preoperative thyroglobulin antibody levels be used as a marker for well differentiated thyroid cancer? J Otolaryngol Head Neck Surg. 45:312016. View Article : Google Scholar : PubMed/NCBI

30 

Gabalec F, Srbova L, Nova M, Hovorkova E, Hornychova H, Jakubikova I, Ryska A and Cap J: Impact of hashimoto's thyroiditis, TSH levels, and anti-thyroid antibody positivity on differentiated thyroid carcinoma incidence. Endokrynol Pol. 67:48–53. 2016. View Article : Google Scholar : PubMed/NCBI

31 

Selek A, Cetinarslan B, Tarkun I, Canturk Z, Ustuner B and Akyay Z: Thyroid autoimmunity: Is really associated with papillary thyroid carcinoma? Eur Arch Otorhinolaryngol. 274:1677–1681. 2017. View Article : Google Scholar : PubMed/NCBI

32 

Donegan D, McIver B and Algeciras-Schimnich A: Clinical consequences of a change in anti-thyroglobulin antibody assays during the follow-up of patients with differentiated thyroid cancer. Endocr Pract. 20:1032–1036. 2014. View Article : Google Scholar : PubMed/NCBI

33 

D'Aurizio F, Metus P, Ferrari A, Caruso B, Castello R, Villalta D, Steffan A, Gaspardo K, Pesente F, Bizzaro N, et al: Definition of the upper reference limit for thyroglobulin antibodies according to the national academy of clinical biochemistry guidelines: Comparison of eleven different automated methods. Auto Immun Highlights. 8:82017. View Article : Google Scholar : PubMed/NCBI

34 

Pickett AJ, Jones M and Evans C: Causes of discordance between thyroglobulin antibody assays. Ann Clin Biochem. 49:463–467. 2012. View Article : Google Scholar : PubMed/NCBI

35 

Lee IS, Hsieh AT, Lee TW, Lee TI and Chien YM: The association of thyrotropin and autoimmune thyroid disease in developing papillary thyroid cancer. Int J Endocrinol. 2017:59403672017. View Article : Google Scholar : PubMed/NCBI

36 

Zhang L, Li H, Ji QH, Zhu YX, Wang ZY, Wang Y, Huang CP, Shen Q, Li DS and Wu Y: The clinical features of papillary thyroid cancer in hashimoto's thyroiditis patients from an area with a high prevalence of hashimoto's disease. BMC Cancer. 12:6102012. View Article : Google Scholar : PubMed/NCBI

37 

Baser H, Topaloglu O, Tam AA, Evranos B, Alkan A, Sungu N, Dumlu EG, Ersoy R and Cakir B: Higher TSH can be used as an additional risk factor in prediction of malignancy in euthyroid thyroid nodules evaluated by cytology based on bethesda system. Endocrine. 53:520–529. 2016. View Article : Google Scholar : PubMed/NCBI

38 

Fiore E, Rago T, Latrofa F, Provenzale MA, Piaggi P, Delitala A, Scutari M, Basolo F, Di Coscio G, Grasso L, et al: Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: Role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer. 18:429–437. 2011. View Article : Google Scholar : PubMed/NCBI

39 

Latrofa F, Ricci D, Grasso L, Vitti P, Masserini L, Basolo F, Ugolini C, Mascia G, Lucacchini A and Pinchera A: Characterization of thyroglobulin epitopes in patients with autoimmune and non-autoimmune thyroid diseases using recombinant human monoclonal thyroglobulin autoantibodies. J Clin Endocrinol Metab. 93:591–596. 2008. View Article : Google Scholar : PubMed/NCBI

40 

Sinclair D: Clinical and laboratory aspects of thyroid autoantibodies. Ann Clin Biochem. 43:173–183. 2006. View Article : Google Scholar : PubMed/NCBI

41 

Zhao L, Liu M, Gao Y, Huang Y, Lu G, Gao Y, Guo X and She B: Glycosylation of sera thyroglobulin antibody in patients with thyroid diseases. Eur J Endocrinol. 168:585–592. 2013. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 11 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Xiao, Y., Zhou, Q., Xu, Y., Yuan, S., & Liu, Q. (2019). Positive thyroid antibodies and risk of thyroid cancer: A systematic review and meta‑analysis. Molecular and Clinical Oncology, 11, 234-242. https://doi.org/10.3892/mco.2019.1886
MLA
Xiao, Y., Zhou, Q., Xu, Y., Yuan, S., Liu, Q."Positive thyroid antibodies and risk of thyroid cancer: A systematic review and meta‑analysis". Molecular and Clinical Oncology 11.3 (2019): 234-242.
Chicago
Xiao, Y., Zhou, Q., Xu, Y., Yuan, S., Liu, Q."Positive thyroid antibodies and risk of thyroid cancer: A systematic review and meta‑analysis". Molecular and Clinical Oncology 11, no. 3 (2019): 234-242. https://doi.org/10.3892/mco.2019.1886